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PREFACE

As a first year medical student I naively wondered, what is the
relationship between allergy and cancer?

After all, I reasoned with

a limitless lack of sophistication, the immune system must have something to do with both diseases.

When I posed this question two years

later to John Dwyer, my adviser, I received the answer that stimulated
much of Ttfhat I now report.
to the library.

His reply was, "The question has merit. Go

Find out what you can.

Report back to me."

Duti¬

fully I began to search the journals trying to resolve such broad
issues as do atopies develop cancer as often as normals?; could those
with allergy have a genetic selective advantage in immunosurveillanee,
the rejection of malignant clones before their clinical presentation?;
what is the role of IgE, that immunoglobulin class primarily respon¬
sible for allergy, in responding to neoplasia?

Armed with questions

like these, a pattern was established,

I would read and report;

John

Dwyer would listen, question, suggest.

Slowly we elaborated projects to

resolve specific issues.
The laboratory in which these experiments were undertaken possesses
many skills in immunological research.

In particular, the lab is expert

in assessing T and B cell function and investigating cutaneous basophil
hypersensitivity responses.

The laboratory's lack of prior experience

with research on IgE provided me with great latitude in experimentation,
but this also meant that a substantial amount of time had to be devoted
to basics before the proposed tumor work could be successfully engineer¬
ed

-2-

The thesis then contains three natural divisions.

Part I stems

directly from that first naive question; it is a review of the litera¬
ture regarding the relation between IgE and neoplasia.

Part II de¬

rives from the need to understand some basic properties of IgE,

It

describes studies that have no direct relation to tumor immunology but
includes such fundamental topics as the assay of IgE and the ©ntogenetics of IgE production.

Finally, Part III concerns specifically the

relation between IgE and tumors.
In many ways, this work is unfinished.
defect, but rather its virtue.

This is not the study's

The topics explored were constantly

demanding clarification of results, suggesting further study, and re¬
quiring refinement of techniques.

This thesis project resembles the

process of education by representing the construction of a starting
gate from which to conduct a marathon, not a dash.

While the finish

line has not yet been reached, many hurdles have been cleared and most
important, a direction in which the runners can head has been established.
The naive medical student has changed little since his initial ques¬
tion, but he has discovered that even questions asked out of ignorance
may merit exploration.

PART I:

A Review of the literature

Few topics in medicine are currently generating as much interest
as the relationship between the immune system and malignancy.

Recent

reviews-®-^,208,245 have covered such relevant issues as blocking anti¬
bodies, cell-mediated immunity, tumor associated antigens, immunosurve¬
illance, immunodeficiency, and immunotherapy.

With such a plethora of

interests demonstrating a definite relationship between the immune system
and cancer, not surprisingly all reviews omit any mention of the ambig¬
uous role that immunoglobulin S or IgE plays in response to neoplasia.
Yet much suggests the importance of just this subject.
Background
Basic facts about IgE, which is sometimes called reaginic, skinsensitizing, or homocytotropic antibody, have been reviewed thoroughly
and the reader is referred elsewhere^* ^2 for detailed information.

In

brief, as recently as ten years ago, the antibody responsible for immed¬
iate wheal and flare skin reactions was thought to be a subclass of IgA.
Then, in 1966, careful work by K. Ishizaka and his colleagues showed
reaginic antibody to be a unique class of immunoglobulin,^ ^

This was

confirmed shortly thereafter by the discovery of an IgE myeloma,and
the demonstration that antisera to the myeloma protein could absorb re¬
aginic activity from serum,Several parasitic infections^71*196,210
and atopic diseases^® including asthma,1°3»121 allergic rhinitis,^14
and atopic eczema^*® ^ are often characterized by elevated levels of IgE.
Reagin is thought to be primarily responsible for immediate type hypersenstivity responses such as anaphylaxis.

Some evidence suggests that

IgE might have a role in such diverse entities as Graves' disease^39
and the nephrotic syndrome.70,133

IgE is present in the serum in ex-

4-

-

tremely low concentrations,^®^ nanograms per milliliter, and is also
tissue bound to basophils and mast cells„^5@ 99

An IgE-antigen reac¬

tion can trigger the release of potent mediators including hista¬
mine, ^55 siow reacting substance of anaphylaxis(SR3-A)255( and
eosinophilic chemotactic factor.^-®
Intuitive Arguments
The idea that individuals x-dth atopy may have a significantly
lower incidence of malignancy has occurred to many investigators.
intuitive argument could be stated as a syllogism;

One

Cancer begins as a

failure of the immune system, an immunodeficiency; in allergy, the im¬
mune system is over-active or hypersensitive; therefore, perhaps the
immunosurveillance system of an atopic is more likely to reject a clone
of malignant cells before a cancer is clinically apparent.
In rejecting this logic, a response might stress that the patho¬
genesis of atopy should not be considered merely as an excess of IgE or
an exaggeration of the normal immune response.

First, no study has

shown that all those with asthma, allergic rhinitis, or atopic eczema,
have increased total IgE; roughly thirty to sixty per cent of atopies
can be characterized as such,»105»106,121,134,210 although an eleva¬
tion of antigen-specific IgE antibodies does correlate more closely
with the incidence of allergic symptoms,-^4
have other immune aberrations.

Second, atopies clearly

Recent studies have suggested that T-

cell function, both as tested in vivo by delayed hypersensitivity skin
testing and in vitro as tested by mitogen stimulation, is depressed in
atopic disease,*^5,138,155,262 although studies in our lab and else¬
where have not confirmed these findings,38,52,55»65

s©rafini has shown

5-

-

that allergic patients have markedly increased autoantibodies of the
thyro-gastric group.

203

Evidence suggests that reaginie antibodies

are qualitatively and not just quantitatively abnormal in atopic persons,~^

Some have contended that the primary / immune disturbance in

allergic individuals is actually a transient IgA deficiency, not an
IgE elevation.

c

And numerous excellent studies in animals are

demonstrating the role of the T-cell in regulating IgE.’ 9»81,174-176,
222-225
A second intuitive argument considers genetic laws.

The inci¬

dence of atopy may be as high as twenty-four percent of the population. 207

Allergy has long been recognized as familial'J and now

. ,
.
. ,
, 20,21,130,150
,
151,229,230
evidence has mounted that both in
man and mouse
IgE levels are genetically determined.

One would hope to find then

some selective advantage in being allergic, but none has been proven.
While IgE levels are clearly elevated in many parasitic infestations,
only debatable arguments claim any benefit from this elevation.^4’^^*
125,126

gome have suggested that IgE protects against respiratory in-

fections pf IgA is absent'* ' and that possibly the IgE system serves
as a warning about pollutants, but equally good data indicate that IgE

Iga
in the presence of IgA deficiency predisposes to pulmonary disease.
Individuals apparently perfectly normal have been shown to be IgE de¬
ficient. ^2,184
talizing,

Although without substantiation, the argument is tan¬

If a quarter of the population has a genetic defect, namely

the tendency to develop allergic symptoms, then there must be an unre¬
cognized selective advantage somehow involved -with this '’defect".
Hoping to show that this selective advantage involves the response
to tumors, at least nine separate investigations have been published on

6-

-

the incidence of allergy or atopy in patients with malignan¬
cies.56,63,66,139,141,156,159,204,228

The first such study139 pub¬

lished in 1953 actually concluded that patients with cancer, mainly
carcinoma of the cervix in this report, were far more likely to have
allergies (27$) as compared to controls (11$),

The study has several

major defects, however, including the authors' effort to prove an
hypothesis that they had formulated before the investigation, thus
biasing their inquiries, and the lack of age or sex matched controls.
Of the eight subsequent studies along this line, five concluded
that patients with malignancy had a significantly decreased incidence
of atopy, while three studies disclosed no difference between normals
and patients with cancer.

These studies all differ markedly in such

essential parameters as the definition of allergy or atopy, the care
in matching controls, the range in types of malignancy studied, and
the size of the population.
are summarized in Table I.

Some of the findings of all nine studies
The publication of so many reports has

served to confuse rather than clarify, as evidence accumulates that
atopy is both relevant and irrelevant to the incidence of carcinoma.
Total Serum IgE and Malignancy
With the ability to measure serum IgE, however, it seemed that
the controversy could be settled more definitively by simple assaying
IgE in the serum of normals and those with cancer.

Indeed, at least

four groups of investigators have tried this approach, but here, too,
opinion is not unanimous,
Augustin and Chandradasa

13

were first to publish their results on

serum IgE in patients with neoplasia in 1971.

Using a radial immuno¬

diffusion technique to measure IgE, they found that the mean serum value
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of this immunoglobulin was depressed in 65 patients with cancer as
compared to 50 controls.

But IgE levels were also decreased in 48

hospitalized surgical patients.

No statistically significant differ¬

ence was found between the cancer group and the surgery controls or
between the surgery patients and the normals.Still» this report is
often cited as one that shows decreased IgE in patients with cancer.
In 1972, Jacobs et at.

102

measured IgE levels in 50 patients with

allergy, 100 normals, 200 with untreated advanced carcinoma, and 200
with carcinoma undergoing chemotherapy with cyclophosphamide.

Both a

radial immunodiffusion and solid phase radio-immunoassay (RIA) were
used.

Most of the tumors were bronchogenic carcinomas.

While the major¬

ity of cancer paitents had low levels of IgE, many of the untreated sub¬
jects had falsely elevated serum levels as shown by the high levels by
RIA and undetectable values by immunodiffusion.

This false elevation may

be due to an auto-antibody which is also present in normal sera and is of
unknown significance.

l60

Other authors have also found autoantibodies

against IgE in normal serum.

1 242
*

Q

Arbesman et al,7 utilised their own radio-radial Immunodiffusion
technique to evaluate IgE levels in patients with various diseases includ¬
ing malignancy.

Of 282 patients with cancers, 32 had what the authors

considered to be an elevated level, greater than 300 units per milliliter,
like the two previous studies, they conclude that IgE seems to be de¬
creased with malignancy, but no statistically significant difference was
proven between the cancer group and the blood bank donor controls.
The study of Waldmann et al. J

was most recently published.

main advantage of their work is the use of a double antibody radio-

The

8

-

-

immunoassay^2 which is particularly sensitive when low values of IgE
or non-specific interference with the assay are possibilities.

~J

Their data is also submitted to statistical analysis and includes only
immunoglobulin levels of patients on first admission to the hospital,
thereby eliminating the complication of therapy possibly altering IgE
levels.

Studying 331 cases of neoplasia, the authors conclude that

IgE levels are generally normal with cancer.

However, patients with

B-cell malignancies such as multiple myeloma and chronic lymphatic
leukemia do have depressed levels of serum IgE just as they have depression of other immunoglobulin classes.

231

This is often explained

as a crowding out of the normal B-cell or antibody-producing precursors
by neoplastic cells.

Finally, and most intriguingly, patients with

Hodgkin’s disease have clearly elevated levels of IgE which the authors
suggest may be due to a depression of T-cell function,

Arbesman et al.

9

had likewise shown elevated levels correlating with the stag© of the
disease.
Numerous investigators are actively exajdh&fgthe role of the T-cell
in regulating IgE responses.

Host manipulations that destroy T-cell

function including thymectomy,^5 irradiation,-^,1?5 and treatment with
anti-lymphocyte serum

seem to favor IgE production.

One group has

isolated a soluble factor from thymocytes that can suppress an IgE response.

223

Since Hodgkin’s disease has decreased T-cell function with the

incidence of anergy correlating with the stag© of the disease, a possible
cause of the elevated IgE especially in stag© III and IV disease, becomes
apparent,
Although the association may just be coincidental, Hodgkin's dis¬
ease is associated with two phenomena also related to IgE, The neph-

9

-

-

rotic syndrome not infrequently accompanies Hodgkin's disease, and as
IgE may be a causative factor in some forms of nephrosis, at least one
physician has speculated that the nephrotic syndrome in Hodgkin's
might be related to an IgE response.^

Second, fifteen to twenty per¬

cent of Hodgkin's disease patients have eosinophilia,^ some to a very
marked degree,and the speculative possibility exists that this
is related to reagin,
Hodgkin's Disease in an Animal Model
The SJL mouse strain develops a spontaneous neoplasm often considered to be an animal model of Hodgkin's disease.

3

Paradoxically, in

published reports so far, this mouse has been shown to be a very poor
producer of reagin^^ and it has even been noted, that its failure to
make IgE might relate to its tendency to develop tumors,Despite
its seeming inability to produce IgE, the SJL mouse has been reported
to be among the most susceptible mice to anaphylaxis,

227

although mice

have reaginic antibody other than IgE and non-reaginic factors may also
mediate anaphylaxis,
Haran-Ghera et at,

82

have made a thorough study of the SJL mouse

in order to consider the possibilitycf predicting by immune parameters
which individuals irould develop the spontaneous reticulum cell neoplasm
resembling Hodgkin's.

Examining such criteria as presence of antinuclear

antibodies, antibody response to sheep red blood cells, and rejection of
skin grafts, they were unable to distinguish those animals that were to

235
develop tumors,

Warren

has shown that SJL mice make a poor immune

response to schistosoma mansoni eggs when compared to DBA/2 controls.
His criterion for response was the size of granulomata in the lung six-

-10-

teen days after the eggs were given intravenously,

As many believe that

IgE is a crucial factor in responses to parasites, a poor reaginic res¬
ponse might account for the smaller granulma in SJLs.
With the evidence that humans with Hodgkin's disease have increased
IgE but that animals that supposedly develop a Hodgkin's-like tumor have
low IgE levels, further study is needed.

What, for example, are the IgE

levels in the mouse after the onset of tumor?

Could variability in mak¬

ing IgE have predictive value as to which animal will develop the neo¬
plasia?

These studies would be facilitated by the ability to measure

total serum IgE in the mouse.

This can be done in the rat^2,42 thanks

to the discovery of IgE myeloma proteins in this
tumors have not been described in the mouse.

^3 but comparable

species,

At present mouse IgE levels

can be titered only in relation to a specifics anti os by the method of
passive cutaneous anaphylaxis,

(See methods in Part II.)

Tumor-Specific IgE Responses
Since nine studies have failed to show conclusively if atopies have
a decreased incidence of carcinoma, and four studies on serum IgE seem
now to point

normal levels of IgE in malignancies except in Hodgkin's

disease (for which a few authors would even question its status as a
neoplasia)\ can IgE still be playing a significant role in response to
neoplasia?

Some experimental work published in 1958 strongly suggests

that IgE may play a critical role in responding to some tumors,
74
Seventeen years ago, Grace and Kondof reported on eight patients,
give with breast cancer, two with Hodgkin's and one with a lymphoma, all
of whom had "heat, edema, and tenderness" locally about their tumor,

With

extracts of each tumor, they produced a wheal and flare reaction within
fifteen to twenty minutes after an intradermal injection into the patient's

11-

-

own skin, an immediate hypersensitivity response as is mediated try IgE,
As controls, patients had no reactions to saline or normal tissue.

As

added proof, the reaction could be pqssively transferred by first in¬
jecting a normal volunteer with appropriate serum intraderaally and
one day later challenging that site with solubilized tumor antigen.
This classic Prausnitz-Kustner (P-K) reaction following a twentyfour
hour sensitization must be mediated primarily by iggf91#186,211

as

IgE was not known to be a distinct antibody class until 1966, the true
significance of this report has been overlooked.

The paper is usually

cited only to show that antibodies, but not specifically reaginic anti¬
bodies, were made against the tumor.

A P-K reaction was also demonstrated

73
by Grace and Dao J in a patient with breast cancer and dermatomyositis, and
later by Curtis et al.

again in a paitent with dermatomyositis, though

this patient had a primary carcinoma in the signoid colon and a metastasis
in the lung from which the extract was made.

Grace was unable to pro¬

duce the reaction unless the patient had some sort of cutaneous mani¬
festation of his malignancy.
The existence of a tumor-specific IgE responses is not at all in
conflict with the concept that total serum IgE is normal in malignancy.
Normal levels of IgE vary widely.

For example, the lower limit of normal

was one hundred and thirty times less than the upper limit of normal in
one study.

72

Obviously a very significant amount of tumor-specific IgE

could be produced and total serum levels of IgE might still remain within
a normal range.
Only in 1972 was an animal study published proving that a mouse
could produce IgE specific for a tumor,

Partholomaeus and Keasz

16

achi¬

eved this with the Bl6 melanoma and C57EL/6 mice and also showed that
IgE could be produced against alloantigens in a transplant situation.

-12-

No data in man or animal has as yet been published to suggest if this
IgE response is of benefit to the host.
Some evidence in animals, however, might be related.

Parasitic

infestations have been shown, to act similarly to an adjuvant in stimulating an animal to rpoduce IgE against various antigens,

Keller ©i

al. ^ reported that mice infected with Nippostrongylus brasielensis,
a nematode, were resistant to growth of a syngeneic mammary adenocar¬
cinoma,

In rats, the Walker sarcoma could be inhibted or enhanced de¬

pending on the timing of the parasitic infection and tumor challenge.
These authors suspected reagin but were unable to demonstrate it,
Another study shows that mice with trichinella spiralis have a longer
ooo

survival and a decreased incidence of spontaneous mammary tumors,"'''
Infections with trypanosoma cruzi may similarly affect spontaneous
breast cancer in mice.

As an adjuvant, Bordetella pertussis augments

IgE responses greatly^' and also has value in tumor immunotherapy in

14 137
animal

*

nrp

models and possibly in man.'r

Some speculate that IgE is

the factor responsible for prolonged survival.

14 137
*

For all these ob¬

servations, IgE, however, has not been proven to be the factor respon¬
sible for the tumor resistance and certainly multiple factors have been
affected by the experimental manipulations.
The Implications of an IgE Response?
Some Hypotheses
At least five distinct but possibly related, hypothetical mechanisms
might account for the role of IgE in response to malignancy.
The Gatekeeper Theory
An obvious explanation for the role of IgE is that the release of

-13histamine and other vasoactive substances triggered by igE could be
causing a vascular change that would hasten tumor expulsion or destruction,

As such, IgE or the mediatorsreleased from a degranulating

basophil might not have a direct effect on the tumor but would act
as a catalyst or "gatekeeper",

213

altering vessel permeability and

thus, alloxtfing other mediators, immunoglobulins, or chemotactic subtances to interact with the neoplasm.

Although at first not believed

to activate complement} IgE has now been found capable of activating
the alternate pathway?^>-^0

^ v-pr^ue Df

altering?; permeability,

IgE is said to be responsible for a model of immune complex disease
25
in rabbits. ^

Perhaps the destruction of tissue in immune complex

disease is not too dissimilar from the destruction of a malignant
clone.
Histamine
A second mechanism for the role of IgE involves histamine.

Bourne*^

and Lichtenstein^^ have elegantly reviewed the evidence that hista¬
mine, by stimulating cyclic AMP, can modulate immune responses, in¬
cluding basophil degranulation, cell-mediated immunity, antibody produc¬
tion, and neutrophil phagocytosis.
retards all of these processes.

In in vitro experiments, histamine

If IgE can be directed specifically

against a tumor, it would be expected that the IgE response would lib¬
erate histamine.

Indeed, in a rat model it has been shown that after

immunization with tumor and B. pertussis adjuvant, tumor challenge
seven days later will release histamine from peritonei exudate cells,
presumably via reagin.^^
If in vivo studies confirm the in vitro work on histamine, the
first hypothesis might be that histamine release should potentiate

14

-

tumor growth by inhibiting lymphocyte mediated cytolysis.

-

However,

histamine seems to have so many possible roles that the inhibition of
tumoricidal lymphocytes might be balanced by other positive factors.
Histamine receptors have recently been shown to be of at least two
types, H-l and H-2.

31

Conventional antihistamines compete for H-l

receptors such as those responsible for smooth muscle contraction.
The receptors for histamine on the basophil and the lymphocyte are of
the H-2 type, that is blockable by the experimental pharmacologic
agents,

burinamide or metiamide.

With the characterization of hista¬

mine receptors, work should now proceed rapidly elucidating the role
of histamine vis a vis the immune response.
Cutaneous Basophil Hypersensitivity
Understanding a third possible interaction between IgE and tumor
tissue may come with a greater knowledge of cutaneous basophil hypersensitivity (CEH).J This skin reaction to antigen is characterized by
a delayed onset in time similar to classic delayed hypersensitivity, but
the histology is marked by a high percentage of mast cells or basophils,
CEH can be transferred with serum,

but since heating the serum to 56°C

does not destroy the capacity to transfer,
be the serum factor.

12

IgE alone would not seem to

Still, with the surface of the basophil marked

primarily by IgE, it is hard to believe that the basophil could be invol¬
ved without the principle immunoglobulin on its surface membrane somehow
participating, possibly even in a negative sense.
Further, in animal models CEM has clearly been demonstrated to have
a role in tumor rejection.

54

In man the potential for CEH reactions can

be monitored by a method called the skin window similar to delayed hyper-

y

-15sensitivity skin testing.

Antigen is placed over a skin scratch and the

area covered by a coverslip.

Periodically the cellular exudate collect¬

ing on the slip is examined, and the percentage of basophils counted.
Using this method, Elack and Leis

32 33

have found that patients with

breast cancer react to their autologous tumor with a basophil-laden
exudate.

They have found that the percentage of basophils correlates

with the sinus histiocytosis in the regional lymph nodes at the time
of surgery which in turn correlates with favorable prognosis.

The cru¬

cial role of the basophil awaits fuller clarification, but surely IgE
will be found to have a hand in its work.
The Eosinophil
Fourth, IgE has been closely linked with eosinophilia.

Eosinophils

are prevalent in allergies and parasitic infections, and a high peripheral
eosinophil count is not uncommon with neoplasia.The ©©sinophil pro¬
duces an enzyme, arylsulfatase, that neutralizes SRS-A^^ and eosinophils
may inhibit histamine relase from basophils.
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Kay and Austen

1X0

have

demonstrated that IgE can cause the release of an eosinophilic chemotactic factor (EOF) and ectopic production of EOF has been shown in a case
237
of carcinoma.

In a phenomenon termed radiation-related eosinophilia,

patients with pelvic or abdominal carcinoma who receive supervoltage
irradiation may develop an eosinophilia which actually correlates with
their prognosis.

The evidence is only circumstantial but it is tempting

to speculate that radiation stimulates IgE perhaps try altering the anti¬
genicity of the tumor or by reducing suppressor T-cells.

The increased

IgE might cause the eosinophilia and either the IgE itself or the eosino¬
phil might favor the host response over the tumor..

Such reasoning is

-16plausible but highly speculative, and eosinophils, like IgE, may be
working toward the patient's detriment rather than his health.

Also,

although only studied in four patients, total serum IgE has not been
found elevated in radiation-related eosinophilia,
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T-cell Function
Finally, unraveling the relationship between IgE and the T-cell
should be crucial in understanding the role of IgE in response to malig¬
nancy,

Generally the T-cell is thought to be primarily responsible for

cell-mediated immune responses that can aid the host by destroying tumor
cells, while a humoral or E-cell response to a tumor can have a variable
prognostic effect and may account for enhancement of tumor growth via
blocking antibodies.
Besides Hodgkin's disease, other illnesses with decreased T-cell
function may have elevated IgE.

In infectious mononucleosis, which is

frequently characterized by anergy,-^ jgg may be transiently elevated
In sarcoidosis, which is known to be associated with frequent anergy,
Gentian investigators found IgE higher than in normal and tuberculous
controls.
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And in atopy, as previously alluded to, while most think of

the primary immune dysfunction as increased IgE, several have found de¬
creased T-cell function.
If decreased T-cell function is the primary defect causing elevated
IgE, several paradoxes arise.

First, besides being responsible for
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suppressing IgE, the T-cell bears a factor that enhances IgE product!on,

so one must posit that this function is intact while the suppressive func¬
tion is abrogated.

Second, many diseases can be shown to have diminished

T-cell function, including commonly most malignancies

Why should

17

-

-

no t any tumor with depressed cell-mediated immunity have increased IgE?
Third, how can measles vaccine simultaneously suppress both atopic sym?2 65
toms and T-cell function.
Possibly IgE accounts for negative feedback to the T-cell.

Acting

via histamine or other mediators, it may be IgE capable of suppressing
the T-cell as well as the T-cell capable of suppressing IgE,
Conclusions
At present, the relationship between IgE and other functions of
the immune system is confusing.

No unifying hypothesis has been able

to relate IgE, the T-cell, CBH, histamine, and the eosinophil.

Consider

these puzzles.
Many patients with ataxia-telangiectasia have absent IgE
this disease has a high rate of lymphoma at very young ages.

7,184
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and

On the

other hand, some of the highest IgE levels have been recorded for patient's
with Wiskott-Aldrich syndrome " J
in life.'^

and they, too, develop neoplasia early

If IgE abets a host response toward the tumor, why is T-cell

function supposedly depressed in atopic eczema and why does histamine turn
off tumor cell lysis?

Are atopies more likelsr than others to produce an

IgE response toward, a tumor?

If a tumor-specific IgE response is demon¬

strable, what effects does it have on the prognosis?

What is unique about

Hodgkin's disease when other malignancies do not have an elevated IgE?
An intriguing area for studying the role of IgE in response to neo¬
plasia might come from understanding the pathophysiology of dermatologic
manifestations of malignancy.

Although its role is uncertain, IgE has been

,
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implicated in a variety of dermatidides, not just atopic eczema.
diseases like dermatomyositis, erythema multiforme, and pemphigoid,

In

-18diseases which may herald an occult malignancy, IgE may prove to be
active in the pathogenesis of skin signs.

In all the reports of either

Grace or Curtis in which P-K reactions were demonstrated for tumor pati¬
ents ^ the individuals had some cutaneous manifestation of the tumor,
Arbesman has found that IgE is commonly elevated in patients with

8

pemphigoid and in the fluid of its bullae,''

All of this information

suggests that the area of IgE, carcinoma, and skin signs demands fur¬
ther exploration.
While many riddles remain to be solved and questions need to be
answered, the role of IgE in response to neoplasia is emerging as a
provocative topic for study.
Experimental Design and Rationale
Desiring to clarify the relationship between IgE and neoplasia,
we designed experiments to help resolve some of the specific issues
raised in this literature review.

Some of the studies explored directly

the relation between IgE and a tumor; these are described in Part III,
Other studies stemmed from a need to understand certain essentials of the
IgE response and to perfect a serum assay.

These studies were logical

preliminaries to those described in Part III and will be considered in
Part II,

The value of undertaking these preliminary projects can perhaps

best be demonstrated by first explaining the projects with a direct rela¬
tion to tumors.
In Part III, one finds experiments toj

1) demonstrate an IgE res¬

ponse to tumor in animals, 2) evaluate the ability of an animal bearing
tumor to make reagin 3) measure IgE levels in children with neoplasms
and 4) show that humans can make a tuma^specific IgE response.

19-
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Demons trating IgE responses to tumor in animals was a repetition
of the work of Bartholomaeus and Keast, but it was essential in order
to evaluate what effect this IgE response had on the course of the
malignancy.

Evaluating the ability of an animal with tumor to make

reagin was designed to answer whether low serum IgE in patients with
cancer or high serum IgE in Hodgkin's disease was a cause or effect of
the tumor.

Measuring IgE levels in children with cancer was a test of

the genetic hypothesis that atopies have a selective advantage in resis¬
tance to neoplasms.

Finally, showing that man can make tumor-specific IgE

was a way of duplicating the work of Grace and others without asking
healthy volunteers to accept injections of tumor antigen as is done in
the P-K reaction.
With these projects in mind, x-re undertook the preliminary work des¬
cribed in Part II,

Obviously in order to do the xrork on childhood neo¬

plasia, we needed to be able to measure serum IgE.
RIA for IgE is the first study described.

So our work with a

Second, as we were going to

be measuring IgE, we wished to be certain that the time of day that the
sample was drawn was not influencing the serum level.
diurnal rhythm for IgE was a necessary undertaking.

So ruling out a
Finally vie conducted

experiments to delineate the ontogenetics of IgE production in the neonatal
mouse, that is, the relation of IgE to IgM, G, and A.

We realized that

such a project would not directly reveal the interplay between IgE and
tumor, but understanding the normal physiology of the IgE response -will be
essential in understanding the factors that determine an IgE response in
a patient -with cancer.

For example, the ontogenetic model that we devised

should allow us to study the relationship between IgE and IgA deficiency.

20-
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The breast can produce secretory immunoglobulin and evidence suggests
that an IgA response may be prognostically significant in women treated with radiation following mastectomy.

On the other hand, Grace's

work showing P-K reactions in five patients with breast cancer and
Black's studies that show that a basophilic response is prognostically
significant in breast carcinoma, both suggest that IgE may be impor¬
tant in breast tumors.

Our work on ontogeny could help elucidate the

interplay of these two secretory immunoglobulins, E and A.

Just as the

explanation for elevated IgE levels in patients with Hodgkin's disease
has derived from studies that furthered the knowledge of the normal
physiology of the IgE response but had no direct bearing on tumor research
at the time they were performed, so we hoped that our work on the onto¬
geny of IgE would further our knowledge of the normal physiology of the
IgE response and perhaps eventually prove relevant to tumor Immunology.

-20a-

PART Hi

Basic Studies

(A) Radioimmunoassay

Cne of the first problems to be solved in order to study IgE was
the perfection of a method to assay its concentration in serum,

A num¬

ber of techniques have been described including a solid phase radio¬
immunoassay (RIA) using sepharose particles (RIST) j1^5 a RIA using
antibody bound to bromacetyl cellulose,
radial diffusion,

q

immunodiffusion,

q 02

21
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a double antibody RIA,'

and mixed immunosorbent RIA,

radio-

1

Of the two methods available commercially at the time of this writing,
immunodiffusion can only detect elevated levels of IgE,
Pharmacia’s radioimmunosorbent test (RIST)

The other,

(Phadebas Test, Phamacia,

Piscataway, N.J.) is a radioimmunoassay essentially identical to that
used by Johansson et at. shortly after their having described the first
known case of an IgE myeloma.
With practice, the Pharmacia method proved adequate for measuring
serum IgE in the high nonaal to elevated range.

However, for values

in the range of 10 to 100 units/ml, still within normal limits, counts
from standards with known, differing concentrations of IgE began to
overlap

and values were not reproducible.

typical standard curve shown in Figure 1,
the difficulty in using this assay.

This is illustrated by the
It demonstrates graphically

Even a group that included Johansson

21

(

himself has cautioned against the method for measuring low levels of IgE

and a comparison study of three methods concluded that the double antibody
RIA is the superior method for both reproducibility and assessment of low
levels.185

Rad ioact i ve Counts

^ IfruRc
J-
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(B) Circadian Rhythms
Wishing to measure serum IgE, we need to explore the possibility
that serum, levels might have a diurnal variation.

While other immuno¬

globulins are not known to have daily fluctuations, IgE is unique in
being present in such low concentrations, having the shortest half
life,^4' and being tissue bound.The symptoms of allergy commonly
vary with the time of day.

And many factors possibly related to

allergic symptomatology do have daily patterns including pollen counts,
plasma cortisols, and circulating eosinophil counts.Conceivably,
then, serum IgE itself might have a diurnal rhythm, perhaps in atopies
if not in normals, and possibly correlating with eosinophil counts.
Multiple determinations, however, were performed on a single un¬
known sample and counts for an individual determination differed by as
many as 1200.

With this range of values on a single unknown, it seemed

doubtful that the method would be reproducible enough to detect the
relatively subtle changes that might occur throughout the course of a
day.
Testing the hypothesis of circadian rhythms of IgE must await
either 1) demonstration of greater reproducibility of values of unknown
sera or 2) perfection of an alternate method to assay IgE,
(C) Ontogeny of the IgE Responses;
The Effect of Ant^-Heavy Chain Antisera
Investigating the ontogeny of the IgE response in mice was a major
concern of this thesis project.

While the results could not directly re¬

solve the relation between IgE and neoplasia, furthering the understand¬
ing of IgE production cannot help but bring us closer to elucidating the

!
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role of IgE in host reactions to malignancies,
Kincade and Cooper first described treating chickens with anti¬
heavy chain immunoglobulin."^

When given in oyo injections of

anti-mu, that is antisera directed against the heavy chain of chicken
IgM, bursectomized chickens not only failed to produce IgM, but also
could not synthesize IgG,

Working with neonatal, germ-free, Balb/C

mice, treatment with anti-mu chain immunoglobulin also prevented
production of the immunoglobulin classes, ^-^>-^3 K,G, <& A.

Treatment

with anti-gamma chain prevented IgG and IgA responses, but not the
response of IgM.

Finally, intraperitoneal injections of anti-alpha chain

precluded the appearance of IgA, but did not affect IgM or IgG.

The

explanation offered by the authors is that ontogenetically the mouse’s
E-cells progress from a sequence of producing IgM to IgG to IgA.

The

anti-heavy chain antisera interrupts this sequence theoretically either
by having a lytic effect on the E lymphocytes or by interfering with
their membrane

receptors.

This work has been repeated by other investigators in mice that were
not kept in a germ-free environment^-^»and in random bred animals
The effect of anti-heavy chain has also been studied on lymphocytes grown
T 7A "I 7Q

in vitro."

*

Studies have confirmed the initial reports with the

modification that IgA producing cells may come directly from IgM precursors.

144 i o
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No reported study has concerned itself with relationships of

IgE to the sequential development of immunoglobulins M, G

A, but the

question has considerable clinical importance.
Several investigators have measured IgE concentrations in patients
with hypogammaglobulinemia, including common variable ’acquired’ and
Eruton’s sex-linked hypogammaglobulinemia.*232,184,8?,269

Each study

has shown that greater than ninety percent of hypogammaglobulinemic sub-
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jects have depressed levels of IgE.

-

However, lot'? levels of IgE, as

has been mentioned, are difficult to measure.

Normal serum levels

of IgE are less well established and vary more widely than the nor¬
mal levels of other immunoglobulins.

Subjects who are apparently

completely normal and who have absent IgE have been reported.

132 184

*

Possibly some of these depressed levels of IgE in these hypogammaglo¬
bulinemia subjects are within normal range.
Several pieces of evidence suggest that IgE might have an on¬
togenetic development independent from the M to G to A progression.
First, Ishizaka et al. have studied the production of IgE in vitro in
primed lymphocytes treated with anti-mu sera,

95

'These lymphocytes were

able to produce IgS despite the presence of anti-heavy chain sera and
the reduction of other immunoglobulins.

However, because this work was

done with primed lymphocytes, i.e. lymphocytes that had been exposed to
antigen prior to the treatment with anti-mu and re-exposure to antigen,
the study merely indicates that the cells producing IgE were unaffected
by anti-mu but says nothing about the possible ontogenetic precursors of
these IgE-bearing cells.
Second, although acquired hypogammaglobulinemia is not a single

2 69

entity, but a group of disorders with a variety of causes, ’ 7 some
hypogammaglobulinemia subjects retain IgE despite loss of other immuno¬
globulin classes.

In an experimental model in rabbits, it is possible

to stimulate IgE without detectable antibodies of other classes appearing 268
In doing immunofluorescence studies on lymphoid tissue, Tada and Ishizaka
reported on one hypogammaglobulinemic subject who appeared to retain
a normal number of IgE-bearing lymphocytes despite markedly depressed

24
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plasma cells or P-cells of other immunoglobulin classes.

221
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Two

other similar patients were devoid of IgE as well as IgG, K, or A
bearing cells„

A recent case report describes a hypogammaglobulinemia

patient x-rho retained normal levels of IgE and suffered from a malab¬
sorption syndrome,^"'
Third, many patients with hypogammaglobulinemia develop anaphylac¬
toid symptoms when being treated with passively administered gamma
globulin.59

Both these observations suggest that the synthesis of IgE

may be preserved while other immunoglobulins are absent.
and Ellis,

Schumacher

however, have studied several hypo gamma globulin emic s and

demonstrated that their basophils do not release histamine in the
presence of foreign gamma globulin indicating that the anaphylactoid
responses may not be due to IgE-mediated reactions,
Fourth, Gajl-Peczalska et al,

67

' reported a case of Eruton*s sex-

linked agammaglobulinemia in which the subject had demonstrated allergic
symptoms and had apparently a normal number of circulating IgE-bearing
lymphocytes while B-cells of other immunoglobulin classes were virtually
absent.

Because of the possible confusion between basophils and IgE-

bearing lymphocytes when studied by immunofluorescence, the conclusions
of this study have been questioned.

195
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A second case report'

describes

another child with Bruton's hypogammaglobulinemia who had positive
immediate hypersensitivity skin tests and who reacted with a wheal and
flare to injections of anti-IgE, thus demonstrating the presence of IgE
on his mast cells despite absent serum levels of other immunoglobulins.
Finally, occasionally patients with severe combined immunodeficiency,
a condition with depressed T-cell as well as B-cell function, will have
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2o7
an 'elevated serum IgE,"
while other immunoglobulin levels are
typically depressed.^
With this conflicting evidence relating to the ontogeny of IgE,
we studied the production of IgE in mice treated with anti-mu sera
from birth.
Methods:
Antisera-

Goat anti-mouse mu sera (lot 4066? and/er lot 40900) was

purchased, commercially from Meloy laboratories, Springfield, Virginia,
An absence of anti-light chain activity, kappa or lambda, or anti-heavy
chain activity other than anti-mu was demonstrated with Ouchterlony gel
diffusion plates.

The purchased antisera was preserved with sodium

azide and was dialyzed against sterile saline to remove this preservative
prior to injection into animals.

Control animals were injected with bevin©

gamma globulin (EGG), Cohn Fraction II, Sigma Chemical Co, EGG was dissol¬
ved in sterile saline at a concentration of 10 mg/ml, passed through a
0,20 micron millipore filter, and stored in sterile glass syringes until
ready for use.
Animals-

Mice were provided from the specific pathogen free colony of

the Biobehavioral Science Research Center of the University of Connec¬
ticut, Storrs, Connecticut, at a nominal cost.

In the preliminary work,

DBA/l mice were selected for treatment with anti-mu as these mice are
especially reactive to evalbumin (0A), an antigen for which IgE anti¬
bodies can be readily demonstrated by passive cutaneous anaphylaxis (PCA)
(see below),
A number of difficulties forced us to abandon the use of DBA/l
mice.

First as mothers, these mice are particularly temperamental and

it was necessary to use surrogate C57B1/10 or C57B1/6 lactating females.
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Second, the animals produce small litters.
relatively small in size.

-

Third, the animals are

And fourth, these mice were especially

sysceptible to stress and infection.

Although we began with roughly

forty DBA/1 infants, only seven (four experimentals and three controls)
were able to survive to the end of the experiment thirty-four days
after birth.
Of these experimental animals that did survive, all were runted
when compared to the controls.

The weights of the two groups were

statistically different by Students' T test, p< 0,0001,

Thus, it was

impossible to tell if the immunoglobulin titers produced by the experi¬
mentals reflected the effect of immunosuppression by anti-mu or the effect
of the runting itself.
These problems were minimized in subsequent experiments with the
use of the first generation products of the mating of DBA/l males and
C57B1/10 females.
size was larger.

These animals had a number of advantages.
The animals were healthier.

mothers was obviated.

The litter

The need for surrogate

And the reactivity of these animals to 0A was

230
at least as great as the reactivity of the DFA/ls. "
Male and female six x%reek old Swiss mice from the Sterling Hall of
Medicine colony, Yale University Medical School, were used as recipients of sera to titer IgGl antibodies by PCA.

Preliminary work had

shown these mice to be comparable to CFW mice (Carworth Farms, Mew City,
New York).
work.

131

CFW are a standard breed used by other investigators for PCA
Two huridred gram male Sprague-Dawley rats were purchased from

Charles River Laboratories, and used as recipients for IgS titration by
PCA as described by Mota and Wong‘S’ and Konig et al.^^
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Injection schedule-

-

The schedule for treatment with anti-mu varied

slightly from litter to litter, but in most cases, neonatal DBA/l
x C57E1/10 mice received their first injection, either antisera or
EGG, x-riLthin twenty-four hours of birth.
day one.

This was considered to be

Animals x-rere given 0,05 cc on days one through four intra-

peritoneally (i.p.) and 0.10 cc on days 9* 16, and 26,
was therefore 0.50 cc.

The total dose

On day 21 all animals were given an i.p.

injection of ovalbumin (OA) (twice recrystallized, Worthington Bio¬
chemical, Freehold, N.J.) 0.1 ug dissolved in saline plus alum, 1.12mg
in a total volume of O.lcc,

The alum was prepared as described by Levine

and Vaz^^ and had a dry weight of 28 mg/ml.

On day 34, thirteen days

after exposure to antigen, all animals were placed under light ether
anesthesia and bled repeatedly througjkthe retro-orbital plexus with
glass pipettes.

Approximately 0,20 cc of serum was obtained per animal.

Titration of immunoglobulin levelsA) PCA;

This technique has been well described by Ovary

177

and others.
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In brief, mouse sera contains two immunoglobulin classes of reaginic
antibody, IgE and IgGl.^>^^ Reaginic antibodies can be thought of as
those immunoglobulins that can passively sensitize the surface of mast
cells or basophils and which cause the release of serotonin, histamine,
and/or other vasoactive substances from these cells when exposed to
appropriate antigentic stimulus.

Unlike IgGl, IgE activity can be destroyed

o

by heating at 56 C or by treatment with 2-mercaptoethanol.

34

In mice,

activity of passively injected IgE will persist after 48 hours by which
time essentially all IgGl activity has disappeared.
To titer XgGl, sera was diluted with saline in a two fold manner
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beginning at a concentration of one to five.

-

The backs of Swiss mice

were shaved and after light ether anesthesia, 0,03 cc of diluted serum
was injected intradermally into the shaved surfaces.
tions of varying dilutions were given per back.

Up to four injec¬

After two hours, the

recipient mouse was again given ether anesthesia and 0.15cc of saline
with 0.7$ 04 and 0.4$ Evans blue (Matheson, Coleman, and Eell, E.
Rutherford, N. J.) was injected intravenously via the retro-orbital plexus.
One half hour after that, the animals were sacrificed and reactions read
by removing the skin from the back of the animal and observing the blue¬
ing at the injection site.

Theoretically immunoglobulin from the pass¬

ively administered serum will sensitize the mast cells in the recipient
animal.

When appropriate antigen is given, the mast cell will degranu-

late, releasing histamine and/or serotonin.

This alters vascular perme¬

ability and allows the extrusion of Evans blue, causing the local blueing
xdiich could be easily read as a positive reaction.

The titer of anti¬

bodies was considered to be the highest dilution of serum causing blueing
of 5 mm or more in diameter in at least two of three mice.

If a dilu¬

tion of 1:5 failed to produce a reaction in a majority of mice, the
titer was considered to be zero.
Titration of IgE antibodies in mouse sera can be done in either of
two ways by using PCA.

Recipient animals can either be mice or rats.

For the mice, administering antigen i.v. 48 to 72 hours after the skin
has been sensitized will detect essentially only reagin of the IgE class.
An alternative method is to use rats, as mouse IgE, but apparently not
IgGl, will bind readily to rat mast cells, ,

Male Sprague-Dawley rats were anesthetized with sodium pento¬
barbital (Diabutal, Diamond Labs, Des Moines, Iowa) approximately
0.80 cc/kg i.p.

The back of the rat was shaved and up to 24 in¬

jections of 0.05 cc of varying dilutions of sera were given per
animal.

Two hours later tha animal was anesthetized with ether and

injected i.v. through the dorsal vein of the penis with 1 cc of saline
containing 0.4$ Ivans blue and 0,7$ 0A.

Half an hour later animals

were sacrificed under ether and their dorsal skin removed.

The titer

was considered to be the highest dilution causing blueing of at least
5 mm in two of three animals.
E)

Ouchterlony plates;

Presence of IgGl and IgG2 was determined by

appearance or absence of a precipitation line when serum diluted 1:5
was allowed to raact on a gel diffusion plate with the appropriate
class specific antiserum provided by Dr. Philip Askenase.

This method

is described by Arnason.^0
C)

Passive hemagglutination:

IgM and IgG antibody levels to 0A were

measured by their ability to agglutinate sheep red blood Cells
coated with antigen.

(SRBC)

Blood was defibrinated and the cells washed.

Red

cells were removed and mixed for four minutes at room temperature with
3 mg 0.1$ CrCl^^HgO (Malinckrodt Chemical, St, Louis) and 3 ml of 0A at
a concentration of 10 mg/ml.

The treated cells were washed five times

and resuspended in normal saline at a concentration of 5$®

This suspen¬

sion was diluted 1:5 in phosphate buffered saline.
Serum to be evaluated for antibody was tested in serial two fold
dilutions beginning at a dilution of 1:10.

Rabbit hyperimmune antisera

to 0A was provided by Dr. Philip Askenase and used for control.

Untreated
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serum was considered to reflect both IgM and IgG antibodies.

-

To

measure just IgG, serum was reacted with mereaptoethanol (Pierce
Chemical Company, Rockford, Ill,) and tested at dilutions beginning
with 1:20.

To 0.1 ml of serum to be tested, 0.3 ml of 0.133 M

mercaptoethanol was added and incubation carried out at room temper¬
ature for two hours.
Serial dilutions of serum were added to autotiter hemagglutinating plates containing the treated SRECs and the agglutination end
point read.

Antibody titers are expressed as the dilution for which

agglutination ended.

Fifteen dilutions were tested for each sample.

If no agglutination occurred at the lowest dilution tested, the titer
was considered to be zero.
Splenic histology-

Spleens were removed immediately after sacrifice

and frozen in liquid nitrogen.
for sectioning and staining.
were prepared.

Spleens were stored at -90cCuntil ready
Microtome sections of four to six microns

Tissue was stained with hematoxylin and eosin and evalu¬

ated -with light microscopy.
Animal survival precautions-

Obviously the survival of the animals was

crucial in the performance of this experiment.

Absorption of injections

without rupture of bowel is a delicate technique in a newborn.
injections were skillfully given by Sandra Rosenbaum.

These

To minimize the

risk of cannabalization, we handled all animals i^ith gloves, and during
the first few days of life, rubbed the newborns' backs with Vicks Vapo
Rub (Vicks Chemical Co, Hew York City, NY) immediately after injection
in an effort to discourage the mother from injuring the litter and to
minimize odor from handling.

31

-

-

Results :
The results of treating DRA/l X C578B1/10 mice with anti-nra
antisera and then immunizing with OA are given in Table II.

Mean

values and standard deviations for the EGG treated and the anti-mu
treated groups are given in Table III.
Immunosuppression clearly was achieved,

Students' T test,

the difference between the two groups for IgGl values as determined
by PCA was significant with p<0.025.

Similarly, comparing the IgM

and IgG values as determined by FKA showed p<0.005.
comparison of IgG levels as measured by PHA.

P<0.01 for the

In contrast, the IgE

values did not differ significantly between the two groups (j3>0.3).
Splenic histology is pending.

TABLE II.

RESULTS OF ANTI-MU TREATMENT ON

IMMUNOGLOBULIN PRODUCTION

&

&
Litter Animal Treatment Weight Sex
(gms.)
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4
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A
o o

ANTI-MU

h
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A
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2

PCA

•p
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MO

1280

F

BGG

14.9

80

50003

320

40

+

0

A

ANTI-MU

17.0

640

1280

160

40

+

0

B

BGG

15.8

12802

50005

160

160

+

+

C

ANTI-MU

15.9

640

160

0

0

+

+
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1

IgG
by
PEA

IgGl by

PCA

IgGflgM
by.
FRA

IgB

£
>> u
A ©

1 AH sera tested at 1:5 Dilution
2 Not tested at dilution greater than 1280
3-Values over 5000 are rounded to the nearest thousand
4 The small size of these two animals necessitated combining their sera for
5 NT = Not tested
titration
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TABLE III

MEAN VALUES AND STANDARD DEVIATIONS FOR

IMMUNOGLODULIN LEVELS OF ANTI-MU AND BGG TREATED MICE

Treatment

IgE by

IgG} by

IgG + IgM

p&di

PGA

El PHA

IgG
by
PHA

223 + 387

27 + 53

3990 + 3055

475 + 502

Anti-Mu

382 + 391

5.6 + 12.6

BGG

482 + 495

60,6 + 62,7
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Discussion:
The data indicate that while treatment with anti-mu produced
a statistically significant reduction in anti-OA antibodies of the
IgM and IgG class, anti-OA of the XgE class was not similarly
affected.

The lack of dramatic differences between the two groups

in total serum IgGl and IgG2 as measured by Ouchterlony technique
can be explained by maternal antibodies, especially as animals were
either not weaned or weaned just prior to the termination of the
. 145
experiment.
While a number of clinical and experimental observations on
individuals with hypogammaglobulinemia as

<■.

>

referred to earlier might

have suggested this result, the outcome nonetheless seems counter to
the fact that most hypogammaglobulinemic persons have a significant
reduction in IgE.
Another piece of experimental evidence would certainly seem to
suggest that anti-mu treatment would decrease serum IgE.

Taniguchi

and Tada have recently shown that a solubilized fraction of T-cells
can serve a helper function in immunoglobulin production.This
helper molecule can be absorbed by anti-mu.

They believe that the

helper activity may be an IgT, an immunoglobulin on the surface of
the T-cell.

Unlike IgG, passively administered IgK in small amounts

acts to enhance the production of immunoglobulin

go

including IgE.

23_S

One speculation would be that this effect is mediated by priming
helper T-cells.
One would expect then that treatment with anti-mu would exert a

"33significant effect on IgE production if only by virtue of its po¬
tential action on T-cells.
Abundant evidence, however, indicates that the effect of anti-mu
is independent of T-cells.

In in vitro spleen cell cultures, T-

cells can be removed, but the effect of anti-mu will not be dimin¬
ished,^^

Anti-mu antibodies have a suppressive effect even if the

antigen is thymus-independent such as ferritin.

123

Anti-mu antibodies

can prevent the transplantation of such B-cell tumors as Friend leukemia virus leukemia

149
146
'
or myelomas. '

And anti-mu does not effect

such T-cell functions as skin graft rejection.and possibly helper
function itself.
Still specific T cell functions may be attributable to subpopulations of T-cells

203 2 37

and a subset responsible for assisting

or suppressing the ontogenetic development of the B-cell line might
be affected by anti-mu while other T-cell functions are undisturbed.
If work substantiates that some T-cells bear an IgT with mu chain
determinants,

223.261

one would predict that anti-mu treatment should

affect T-cell function, including helper function in the production
of IgE.

In our work, either helper function was unaltered or a second

effect of anti-mu compensated for diminution in helper function and
permitted normal serum IgE levels.
While treatment with anti-mu suppresses IgK, IgG, and IgA, a re¬
turn to normal levels of IgA despite prolonged treatment with antisera
has been reported.l^sl^

j_s unij^ely that such a rebound is also

occuring with IgE because the return of IgA values was observed only
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after six weeks of treatment whereas at three weeks, the crucial
time in this experiment when animals were exposed to antigen, IgA levels
were always still markedly depressed.

Since, however, the timing and

extent of the reappearance of IgA is dependent on the dose of antimu,l46 we are conducting studies to determine if increasing the
dosage of antiserum might result in a significant depression of IgE.
This experimental model utilizing anti-heavy chain immunoglobulin
has potential for elucidating other aspects about the physiology of
IgE.

For example, the question of affecting IgE levels by selectively

suppressing IgA is especially relevant as some have suggested that the
true immunological defect in atopy is not an excess of IgE but a
transient deficiency of IgA, which may be the only truly significant
blocking antibody,^

As IgE and IgA may both be important fac¬

tors in the immune response in breast carcinoma (see p. 19), this work
could help elucidate the relationship of these two immunoglobulins
in response to malignancy.
Treating mice with anti-gamma 1 and/or anti-gamma 2 may help
clarify the relation between IgG and IgE.

A tradiational view holds that

IgG is the principle blocking antibody and that IgG levels may be
inversely related to IgE.

Support for this hypothesis came when Tada

and Okumura showed that rats given IgG passively produced markedly
depressed IgE titers.

222

However, this report could not be reproduced

by tie Ishizaka and Okudaira'^ in mice, nor could the Ishizakas show
an inverse relationship between IgG and IgE levels during the course of
long tem hyposensitization immunotherapy.91

^ treating slightly older
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mice with anti-gamma we might be able to inhibit IgG selectively
and analyze the relationship between ’blocking* IgG and IgE.
Thus, results so far indicate that synthesis of IgE is either
independent of the ontogenetic progression of other B lymphocytes
from IgM to IgG to IgA or IgE may actually precede IgM in ontogeny.
Current work is in progress to verify these results, especially with
higher doses of immunosuppression, and to elucidate the effect of
anti-alpha antiserum on IgE production.
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PART III;

-

Tumor-Related Studies

(A) IgE Responses to Tumor in Animals

As discussed in the literature review, Bartholomaeus and
Yeast in 1972 reported that mice could make IgS responses to
tumors.

We attempted to repeat their work as a preliminary

to answering some of the following questions:
ponse alter the course of the malignancy?

Does an IgS res¬

Could passive transfer

of IgE affect tumor challenge or the course of an already trans¬
planted tumor?

Is the immunotherapeutic effect of certain adju¬

vants like B, pertussis related to is effect on IgE response?
While Bartholomaeus and Keast had shown that IgS could be pro¬
duced, they had not addressed themselves to any of the above ques¬
tions ,
To assess the role of IgS we attempted to produce a variable
antibody response by using a range of immunizing doses of tumor
and two different adjuvants,
Methods;
Animals-

Male and female AKD2F1/J, DBA/2J, and C5?8l/6j mice were

purchased from Jackson laboratories, Bar Harbor, Maine,

Swiss mice

were obtained from the Sterling Hall of Medicine colony, Tale Medical
School,

CFW mice were purchased from Carworth Farms, Hew 1'■: ’ City,

New York,

Lems rats were purchased from Microbiological Associates,

Recipient animals for PCA titrations were either Swiss or CFW mice
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The Lewis rats had been shown to be comparable to

iprague-Dawley rats in PCA reactions to OA as described in the
previous section.
Tumors- A murine lymphoma, L5178Y, maintained in vivo was pro¬
vided for us by Dr, Robert Capizzi.

Ms tumor was initially re¬

ported in DEA/2 mice and in our hands took readily in AKD2F1/J mice
at i.p. doses of 1<P to 10^ cells.

Death preceded by ascites

occurred regularly in 10 to 18 days depending upon the number of
malignant cells initially injected.

This tumor was selected be¬

cause some immunological aspects of its growth had previously been
studied^»^anc^ ^t was ciear that injecting animals with
irradiated cells could produce immunity,^
The murine melanoma, B16, was given to us by Dr. Ted Reid, who
maintained an in vitro cell line.

This tumor took readily in C57EL/6

mice and caused death in 1? to 35 days.

It is the same tumor as initi¬

ally reported upon by Bartholomaeus and Feast.
Immunization of animals and serum collection-

For the work with L5178Y,

a variety of mice strains including AKD2F1/J, DBA.2J, CFW, Swiss, and
C57HL/6J were given injections of tumor in doses ranging from 1.4 x 10^
to 2.8 x 10^ cells.

The cells were usually viable, but in some instances

they were Irradiated prior to injection.
(s.c.) route of injection was used.

Either an i.p. or a subcutaneous

Cells were either given without

adjuvant, with 1 mg of alum, or with killed B. pettussis organisms (Eli
Lilly and Co., Indianapolis, Ind.) with the number of bacteria varying
from 9.6 x 10^ to 4,4 x 10^ depending on the trial.
previously described.

181

Alum was prepared as

Mice were bled from seven to nineteen days after an

-38an initial injection of cells or following a booster injection of
tumor.
For work x$ith the Bl6 melanoma, 6 C57E1/6J mice given a s,c. in¬
jection of 3 x 105 cells plus 1 mg, of alum.

Serum was obtained from

these mice one and two weeks after immunization.
For all animals, bleedings and i.v. injections were usually
performed with the animal under light ether anesthesia.
Irradiation-

"When cells were irradiated, a Semens x-ray machine was

used with a 2 A1 filter,
delivers 500 rads/min.

When set at 250 KV and 15 ml, this machine
Three to five thousand rads were given cells

depending on the trial.
Passive Cutaneous Anaphylaxis (PCA)-

PCA reactions were performed

as previously described with recipient animals including Swiss and
CFW mice and Lewis rats.

Antigen prepared from tumor cells was given

in the solubilized forms as described below.

Antigen was usually

given i.v,, but in some trials the antigen was given intradermally (i,d.)
directly into the site that had previously received serum passively.
"When antigen was given in this manner, a control injection of antigen
into unsensitized skin was also tested.
Active Cutaneous .Anaphylaxis (ACA)~

In a few instances, antibody res¬

ponse was assayed by injecting an animal with antigen i.d. some time
after that animal had been actively immunized with tumor cells.

The

animal receiving the i.d. injection would first be shaved, receive the
injection of intradermal antigen, then immediately receive an injection
of Evans blue x^ith saline i.v.

Thirty minutes later tha animal would

be sacrificed and reactions judged from the underside of the skin.
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Control reactions included injection of saline instead of tumor
antigen and injection of tumor antigen into non-immunized animals.
Positive reactions may be attributable to either IgS or IgGl,
Solubilization of tumor antigen-

A positive reaction in PCA requires

that antigen react:on with IgS on the surface of a basophil or mast
cell.

For steric reasons, we believed that this reaction would be

difficult to elicit without first solubilizing the tumor antigen.

Al¬

though in a few instances whole tumor cells -were used to attempt to
elicit the PCA reaction, we generally solubilized the antigen by one
or more of the following procedures:

rapid freezing and thawing in a

dry ice-acetone bath; ultrasonication with a sonifier call disruptor,
Model W185D, Heat systems-ultrasonics, Inc,; ultracentrifugation at

30,000 RrM or at 30,000 g for one hour;

irradiation with three to five

thousand rads; and extraction with 3 M PCI as described by Meltzer et
al.

162

In order to elicit PCA reactions, antigen was administered i.v. via

the retro-orbital plexus in the mouse or via the dorsal vein of the
penis in the rat.

Either Evans blue was added directly to the tumor

antigen or a second injection of saline plus Evans blue was given imme¬
diately before or after the injection of tumor antigen.

An initial con¬

centration of greater than 10^ cells/ml. and usually greater than 10 ^
cells/ml was always used to begin the solubilization process.
Foot pad testing-

An index of delayed hypersensitivity response to

jLi'jySY was assessed by injecting appropriate antigen into the foot pad of
immunized mice.

Antigen injected into one foot was 0.04 ml of irradiated

cells at a concentration of 1.25 x 10

cells/ml.

The other foot pad re¬

ceived 0,03 ml of tumor antigen extracted with 3 M KC1,

Foot pad thick-
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ness was measured prior to injection and twenty-four hours after
antigen.
plus 10

8

Mice tested included 3 AKD that had received leP L5178Y
^

B. pertussis, 3 Swiss that had received ICr L5178Y twice

with two weeks separating the immunizations, and 3 Swiss mice that
had received no exposure to tumor.

Mice that had been immunized were

tested twenty days after the initial injection of tumor.
Results;
Using the tumor, L5178Y, despite the variety of animals immunized,
the range of bleeding times, the types of adjuvants, the varied routes
and doses of immunogen, and the alternative methods for solubilizing the
antigen, we were unable to produce consistent PCA reactions for either
IgS or IgGl.
Results are summarized in Tables IV and V,
A description of a typical experiment should clarify the procedure
followed.
Five groups of four AKD2F1/J mice were given i.p. injections of
■)

irradiated (3000 rads) L517&Y cells in doses ranging from 3 x 10
3 x 10^ cells.

to

Cells were given with 1 mg of alum in an i.p. injection

of 0.2 cc.

Although 3»000 rads has been reported to destroy the activity

of L5178Y,

by day 18, the majority of animals having received the

maximum tumor dose were dead.

The survivors of this group were bled on

this day and all other groups were bled the next day.

Mice in all other

groups shox-xed no signs of illness and were disease free for at least an
additional six weeks.
for use,

Serum was pooled and frozen at -20°C until ready

L5178Y cells in a concentration of 9.6 x 10^ cells/ml. were

TABLE IV

PCA REACTIONS TO L5178Y FOLLOWING
PRIMARY EXPOSURE TO TUMOR ANTIGEN

Mouse
Strain
and
Number
of
Animals

Tumor immunizing
Dose (cell#)
Tadjuvant
Tirradiation

§ g^
® g 8

PCA
test
antigen(s)

Comments

:ge
rt 1 ®
Q
m
*H

19 1 Freeze/thaw x 3;
Ultrasonicate;
Utracentrifuge
19
30,000 RFM

No morbidity from tumor

3 x 103 l.p, +alum

19

No morbidity from tumor

4AKD

3 x 10** l.p. +alum

19

4AKD

3 x 10^ l.p. +alum

19

One of three animals 0
for IgE at 1:3 Dilution
No morbidity
No morbidity from tumor

4AKD

3 x 101 l.p. +alum
irradiated

4AKD

3 x 10

4AKD

5AKD

l.p, +alum

103 l.p.

7 1 Whole cells,

8
3AKD

1(P l.p. + 10
ssis

pertu-

3 SWISS 103 l.p, + 10® pertussis
3AKD
2.8 x 106 l.p.
o
4AFW
1.4 x 10*7 l.p.
4CFW

1.4 x 10

4CFW

1.4 x 10l l.p.

l.p.

5C57B16 10° + alum S.C.
10

Day 15

+ alum S.C.

7 2 Irradiated cells
3 Sonicated cells

No morbidity from tumor

7

No morbidity from tumor

7

No morbidity from tumor

9 1 Freeze/thaw x 3t
Ultrasonicate;
9
Ultracentrifuge
30,000 g
9 2 Whole cells

Also negative at 14 days
by ACA
Also negative at 14 days
by ACA

9
10 1 Freeze/thaw x 5
8t©10

c

6CFW

10° + alum l.p,

10

3AKD

103 + 10® pertussis
l.p.
103 l.p

14 1 Irradiated cells
2 KC1 extract
3 Intrademal KC1
Extract

3AKD

Animals dead

ie8/ml

103 l.p.

3 SWISS

4DBA/2

Animals dead or moribund
by Day 18

2,5 x 10^ l.p. + Per¬ 18
tussis irradiated

3AKD

No morbidity from tumor

Also negative at 14 days
by ACA
Minimum dilution tested
1:2; No morbidity from
tumor
Minimum dilution tested
1:2; Death 12 days
Minimum dilu. tested 1:2
No morbidity from tumor
No morbidity from tumor
Animals dead Day 15
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solubilized by freezing and thawing three times, ultrasonicating
with the sonifier intensity set at 4,5 and 7 bursts of 3 to 5 seconds
given to the suspension of cells surrounded by an ice water bath, and
ultracentrifuging at 30,000 RPM for one hour.

The supernatant was

used as the antigen to elicit PCA reactions.
Each of the Swiss and CFW mice recipients for PCA titration re¬
ceived 0,1 ml. of antigen i.v.

This administration -was given either

two or 48 hours after the animal had been passively skin sensitized
with a dilution of serum of at least 1:5 from the actively immunized ani¬
mals.

With one exception no positive reactions were elicited.

The

one exception occurred after a 48 hour sensitization period at a
dilution of 1:5 with serum from the group that had received 3 x 10^

,

cells

but as this reaction occurred in only one of three animals, it

was not scored as positive when (judged by criteria generally used for
scoring PCA reactions, namely a positive response in the majority of
animals tested.
ACA responses in Swiss mice that had received ICp leukemic cells
26 and again 12 days previously were tried with irradiated cells and
with the hypertonic KC1 extract.

Reactions in the immunized mice did

not differ from controls.
Experimentation with the Bl6 melanoma also did not produce consis¬
tently psoitive results.

As described in the methods section, 6 C57

mice were immunized with a s.c, dose of melanoma and alum and then bled
7 and 14 days after immunization.
and diluted 1:5 with saline.

The sera was pooled from each bleeding

Tumor antigen was solubilized by harvesting
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5 x 10 ^ cells growing in vitro and “freezing and thawing them
rapidly five times in a dry ice-acetone bath.

Four Swiss mice

were skin sensitized and two hours later each received an injection
of Pvans blue i.v, followed by 0,15 ec of the solubilized antigen.
In each case the mouse receiving antigen died within ten minutes of
the intravenous injection of an apparent cardiorespiratory arrest.
Death was clearly not due to the ether anesthesia that had been used
to facilitate the giving of i.v, injections as usually the animal was
visibly recovering from the ether before respiratory difficulties
developed.

Death was also not due to the volume of fluid adminis¬

tered as mice in our hands had been shown to tolerate far greater fluid
loads quite well.

Pulmonary emboli from particles in the antigenic

suspension was considered a possibility, but centrifuging the antigenic
fluid to remove possible particles did not seem to affect the toxicity
of the challenge antigen.

This antigenic suspension was also lethal to

animals that had received no passive serum.
Thirty-four days after receiving the s.c. melanoma injection, three
of the survivors received an i.d, injection of tumor cells that had been
ultrasonicated.

One of the three animals produced a reaction markedly

larger than the response produced by a similar injection into unimmunized
controls.
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Discussion:
While the lack of consistent positive results prevented us from ass¬
essing the effect of an IgE response on tumor growth in an animal sys¬
tem, useful information did emerge from this work.
In their report on mice producing an IgE response to the Bl6
melanoma, Bartholomaeus and Keast solubilized the tumor antigen by a
process of freezing and thawing, ultrasonication, and ultracentrifugation
While we wished to duplicate their work as closely as possible, we were
loathe to ultrasonicate and ultracentrifuge the tumor cells,

Ultra¬

soni cation, if done at too high a frequency, can serve to destroy antigenicity rather than solubilize it.

10 ft

Unfortunately, in their report

Batholomaeus and Keast did not specify the frequency with which they
sonicated.

We also reasoned that ultracentrifugation would only cause

the loss of some antigen.

For these reasons, in most of our work we

solubilized the El6 cells only by rapid freezing and thawing, and the
intravenous administration of this suspension proved lethal to passively
sensitized animals,
A personal communication from Bartholomaeus clarified some of our
difficulties,^

First, the frequency of their ultrasonication was re¬

ported as ranging from 16 to 24 KGS,

As the ultrasonifier that we

employed performed at 20 KCS^ ultrasonication would probably not have
destroyed antigenicity.

The positive active cutaneous anaphylaxis res¬

ponse obtained in one of three animals using ultrasonicated antigen is
encouraging and Confirms the idea that sonication would not destroy all
antigenicity.

16
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Second, the author reported that while they had been success¬
ful in demonstrating IgE responses with a variety of tumor systems,
they had been unsuccessful with all leukemias and lymphomas.

Hence,

our failure with L5178Y despite careful adherence to the methods of
Bartholomaeus and Feast in some of the trials with this tumor be¬
comes understandable.
In trying to interpret our negative results, we could not be
sure if they arose from a failure of the immunized mice to produce an
antibody response or from a failure of our antigen to be solubilized.
The communication from Bartholomaeus re-emphasized the necessity of
using some solubilization procedure to elicit the PCA.

We had some

evidence that mice were making an immune response to the tumor, namely
the mouse's ability to survive tumor challenge.

For example, 3 AKD2F1/J

mice were given lCr L5178Y i.p. and three were given an equal number
Q

of tumor cells plus 10° heat killed Bordetella pertussis,

16 to 18 days

after this injection, the animals from the first group were dead.

Eight

weeks after the injection the animals that had received tumor plus B.
pertussis showed no evidence of disease.

As shown in Table IV, despite

the acquired immunity, we were unable to demonstrate the presence of
either IgGl or IgE antibodies directed against the tumor in these mice.
Foot pad testing like^wise failed to demonstrate the acquired immunity.
While B pertussis has a variety of effects on the immune system,
many investigators have utilized its potent adjuvant effect on IgE
responses.

Furthermore, several authors have noted that like baeille

.

’

■
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calmette guerin

19 76 127
48
’
’
and corynebacterium parvum,
B. per-

tussis may be used to prolong survival in animals bearing tumors.
14,137,247
plasia.°

-
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It has also been tried in immunotherapy of human neoLike other immunotherapeutic agents,

timing of its

administration in certain ways may also enhance tumor growth.
Some authors have speculated that the effect of pertussis on XgE and
the effect on survival after tumor challenge might be related.

With

this in mind, to attempt to demonstrate IgE in pertussis immunized
animals seemed logical.

Negative results, especially as all the work

with pertussis was done only in the lymphoma system, do not rule out
the possibility that IgE might be an important factor in immunotherapy
with B. pertussis.
An outgrowth of these experiments was the observation that when the
B16 melanoma was admixed with alum prior to its inoculation, the sur¬
vival time of the mice seemed to be prolonged 50$.

The alum was pro¬

bably not toxic to the tumor cells prior to the injection, as the alum
was buffered and in an isosmotie medium, although this possibility was
not ruled out by examining the viability of tumor cells combined with alum
in vitro.

Alum itself might prove to have some use in tumor immunotherapy.

We are unaware of other reports suggesting prolonged survival using
alum as an adjuvant.
In summary, in an effort to investigate how an IgE response against
a tumor alters the course of the malignancy, an attempt to show that
mice could make an IgE response against a tumor was undertaken.

Exten¬

sive work concerned the lymphoma, L5178T, and a lesser portion of study

.
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was devoted to the melanoma, £16„

IgS responses were not consis¬

tently demonstrated despite the prolonged survivals, indicating an
apparent immune response, and the use of adjuvants, B. pertussis and alum,
which are known to enhance IgS production,

Clarification of methods

in a report describing an IgE response to a tumor was obtained.

This

information along with the knowledge gained in the unsuccessful trials
should enable this work to be successfully completed in the future.
(B) IgE Responses to Ovalbumin
in Tumor-Eearing Animals

Several reports have stated that individuals with neoplastic
disease have depressed circulating levels of serum IgE,

q *jo ino

If

correct, these reports leave unanaswered the question of cause ct ef¬
fect.

Has a low level of IgE predisposed to the malignancy or did the

tumor result in depressed IgS?

Only a very large prespective study

would really answer these questions, but xre attempted to gain some
clues by studying IgS responses in mice bearing tumors and examining
the effect of tumor inoculation on pre-existing IgE levels in mice.

We

are especially interested in reports of increased IgE in patients with
Hodgkin’s Disease.9*198,231

-^is is usually attributed to decreased

3

T-cell function in what is thought by many to be a T-cell malignancy,"
we studied IgE responses in mice bearing a theta positive lymphoma,
L5178Y.

The theta antigen is found on cells of thymic origin.

assessed the effect of a melanoma on IgS responsiveness.
Methods:
Animals-

Mice given living tumor cells were C5?®l/6j mice for

We also
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the melanoma studies or AKD2F1/J mice for the lymphoma studies.
Both were purchased from Jackson laboratories, Bar Harbor, Maine,
PCA reactions were titered in Swiss mice from the Sterling Hall of
Medicine colony (2 hour IgGl reactions) or in Sprague-Dawley rats
(IgS reactions) from either Camm Research (Wayne, N.J.) or Charles
River Labs (Wilmington, Mass,),
Tumors-

Either the L51?8Y lymphoma or the Bl6 melanoma were used as

previously described.

While the lymphoma was usually transferred from

an in vivo cell line, one group of experiments made use of a transfer
from an in vitro line also maintained by Dr. Robert Ca^pizzi.
Irradiationcribed.
Antigen-

Cells were irradiated with 3000 rads as previously des¬

Irradiated cells were used only in Experiment I.
Ovalbumin (2X recrystallized, Worthington Biochemical, Free¬

hold, N.J.) was given i.p. in saline at a dose of 1 ug with approxi¬
mately 1 mg of alum, synthesized as previously described.

Total injec¬

ted volume was 0,1 ml,
PCA Reactions-

These were run as previously described with passively

sensitized mice or rats given i,v. injections of saline plus 0,7 $ 0A and
0.4$ Evans blue two hours after skin sensitization.

Mice were skin sen¬

sitized with 0,03 wl of diluted serum while 0.10 ml was used in the ratsResults:
Experiments were designed to test if the transplanatation of tumor
would affect the IgE response to ovalbumin.
involve the lymphoma L5178Y.

Experiments I through III

In experiment I, tumor was given to mice

that had a pre-existing, high titer of anti-OA antibodies.

In experiment
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II, the tumor was given just prior to the booster antigen.

-

And in

experiment III, tumor was transplanted just before or after the initial
exposure to antigen.

Experiments IV and V are similar except that

they involve the melanoma Bl6.

In the fourth, animals with a well

established tumor were exposed to OA for the first time in the fifth,
animals were given the tumor after a high, boosted antibody titer had
been established.

The data are summarized in the five accompanying

tables (VI through X), with the data from Table VI also represented
graphically in Figures II and III.

Essentially animals bearing tumors

were able to make IgE and IgGl responses comparable to controls and once
an animal had been immunized, transplantation

of a tumor did not

greatly reduce the antibody response, although a tendency toward de¬
pression of the antibody response was seen in some instances.
A few specific comments about each of the experiments are in order.
In the first, (Table VI), high PCA titers were established by immunizing
mice with OA and boosting them 28 days later.

Several days after the
c

booster dose, tumor was transferred either in a dose of KK or 10

2

cells

with one group receiving 10-^ cells that had been irradiated and one group
receiving only saline.

The graphs (Figures II and III) pictorialize

that all four groups were within a two fold range of IgE and IgGl
concentrations at the time of tumor transplantation.
received 10^ cells had all died within 10 days.

The mice that

Irradiation only slightly

delayed the death so that no animals in this group were living at da3/" 15
after tumor transfer.

All mice that received NaCl or 10^ cells survived.

Effect of L5178Y on ongoing, boosted Antibody Response
Table VI Experiment I

Tumor
Strain Dose
Animals
Cell #
# of

6

AKD

6

AKD

6

AKD

6

AKD

Day
Antigen
Given

IgE Titer-Day*
7

12

17

22

IgG-^ Titer-Day*
27

7

12

17

22

27

-35,-7

640 320 160 160 160 1280 1280 1280 2560 1280

10^1. p.

-35,-7

640 160

102l,p.

-35,-7

$40 320 160

80

320

43*

.lcc
NaCl

105l.p.
-35,-7
irradiated

80

80

40

80

640 1280

320

640 1280

640 1280 1280

1280 1280

♦Number of day is relative to last exposure to antigen
Serum from Day ?was collected prior to transfer of tumor
♦♦Serum was collected on Day 21 as animals were moribund at
the time and all dead by Day 22
Blank spaces in table indicate all animals were dead by
that bleeding date

640

640

FtfrURt

1L

THE EFFECT OF L5I78Y ON BOOSTED
IgG,

RESPONSE

2560
1280

Ig G |

Titer

640

\

^

\

x

\

320

X

Tumor (saline) g iven
160

—--

Saline

---10

80

-10
40
-

20

7

10

2
5

5

control

tumor cells-No deaths
tumor cells - All dead
by day 10
irradiated tumor cells —
All dead by day 14

12
17
22
Day Following Booster Dose of Antigen

27

111

X(s OR £

THE EFFECT OF L5I78Y ON ONGOING,
BOOSTED IgE RESPONSE
—-

Saline

control

2

— -10 tumor cells- No deaths
5
-10 tumor cells-All dead
by day 10

1280
640

IgE

Titer

320
160
80
40
20
10

7

12
17
22
Day Following Booster Dose of Antigen

27
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As can be seen, the IgS levels did tend to drop faster and to lower
levels in those mice dying from tenor, but as two fold differences
were obtained in identically treated groups prior to tumor trans¬
plantation, the four fold differences seen after tumor implantation
are suggestive but may not be significant,

IgGl levels tended 'to

decline even less as compared to controls.
In experiment II (Table VII), antigen was given and then tumor
was transferred just prior to the booster dose of antigen.

The mice

receiving tumor were dead or grossly ascitic fourteen days after tumor
transfer.

While the IgS levels do not differ significantly between the

two groups, a marked decline in IgGl levels is noted in the tumorbearing mice just prior to death.
In experiment III (Table VIII), responses to the primary exposure
to antigen were assessed, that is, not booster doses of OA were given.
Tumor that had been maintained in vitro was injected either two days
after antigen, the same day, or three days before.

One group received

the tumor s.c., a route of injection that permits slightly longer survi¬
val, and then was not given antigen until 12 days later when the tumor had
been well established.

One group was given tumor cells that had been

frozen several months.

As can be seen from the chart, all groups except

the one receiving frozen cells produced IgS and IgGl responses varying
at most by a factor of two when compared with the controls that had received no tumor.

The large majority of these animals died within 18 days

of exposure to tumor with one animal surviving completely and one
surviving to 22 days.

If an animal did not appear ascitic when others in

r,

• * •

••

Transfer of L5178Y Prior to Secondary Exposure to Antigen
Table VII Experiment II

# of
Animals

Strain

Tumor
Dose
# of cells

Day Antigen
Given Relative
to tumor
transfer

IgE titer
♦Day 5

*Day 11

IgG-^ titer
♦Day 5

*Day 11

3

AKD

1.2 x 105
l.p.

-24, + 3

320

160

160

160

3

AKD

None

-24, + 3

320

160

320

1280

♦Number of day is relative to last exposure to antigen

*

Effect of L51?8Y on primary exposure to Antigen
Table VIII Experiment III

# of

Day Ag
IgE titer
IgG^ titer
Given
Relative to
Tumor transfer *Day 12 ♦Day 17 ♦Day 12 *Day 17

e+ .
strain

Tumor Dos©
^ cf cens

5

AKD

2 x 104 l.p.

0

20

4

AKD

2 x 104 l.P.

0

5

Animals

5**
0

Frozen

5

AKD

2 x 104 l.P.

-2

80

5

AKD

2 x 104 1. p«

+3

80

10

5

AKD

2 x 104 1. p.

+12

40

10

4

AKD

0

40

None

♦Number of clay is relative to last exposure to antigen
♦♦Only two animals tested? dilution positive in 1 of 2

10

10

10

0

5

/
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th© group were clearly moribund, it was not bled.

-

This was true

of the one animal that survived the course of the experiment.

Animals

that received s.c, tumor died at about thirty days after inoculation
and animals that had received frozen tumor cells also tended to die
by this date.

The death of those animals receiving frozen cells and

their apparent lack of an IgE response will be commented upon in the
discussion.
Experiments IV and V involved the melanoma EL6.

In the fourth

(Table IX), we were attempting to confirm some preliminary data that
suggested that mice bearing this tumor might be able to make a greater
IgE response than controls.

In this preliminary trial, a group of

three mice had been given KL6 plus a alum and three weeks later were
immunized with 0A plus alum.

When they were bled one week later,

their serum had an IgE titer of 1:20 while controls that had just re¬
ceived a comparable OA injection had no detectable titer.
had detectable IgGl.

Neither group

Experiment IV could not confirm this finding as

all groups had no measurable titers seven days after exposure to anti¬
gen.

Thirteen days after antigen the groups still remained comparable,

except that animals that had received s.c. saline did make a signifi¬
cantly higher IgGl titer.

No effort was made to repeat this and no

explanation for it other than individual variation is readily apparent.
While IgE concentrations for Day 13 were not tested at dilutions greater
than l:l60, the qualitative response at high dilutions can give an
approximation of the antibody titer and it was evident that these groups
would have at most a two fold difference in IgE concentrations.

Effect of KL6 on primary response to Antigen
Table IX Experiment IV

# of
Animals

Strain

Tumor Dose
# of Cells

Day Antigen
Given Relative
to tumor
transfer

IgE titer

IgG^ titer

♦Day 7 *Day 13

♦Day 7 *Day 13

Jg
4

C57

9 x 104 S.C.

4

C57

9 x 104 S.C.
+
Alum S.C.

4

C57

4

C57

All
animals
dead

All
animals
dead

+20

0

+20

0

>160

0

10

AltJns S * C #

+20

0

Zl60

0

10

Saline S.C.

+20

0

2160

0

80

♦Number of day is relative to last exposure to antigen

0

• w,
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In the final experiment (Table X)» mice that had been immun¬
ized with OA were given a booster dose 28 days later and a s.c. dose
of tumor six days after that.

On the day that the tumor was given, the

controls had a two fold lower concentration of IgE and a four fold
higher concentration of IgGl.

These differences tended to disappear

after one group was exposed to tumor,

It should be noted that some of

the titrations in this trial did not always establish the precise IgGl
concentration.

The qualitative response at high dilutions suggested

that IgGl concentrations did not differ widely.

As the primary purpose

of the series of experiments was to examine IgE responses with IgGl res¬
ponses used as control data, precise titration of the IgGl response
was unnecessary if the IgE concentrations were within a two fold range.

Discussions:
The data lend little support to the idea that low levels of IgE
arise from depressed IgE responsiveness during malignancy, but pre¬
existing antigen-specific IgE titers do tend to fall after a tumor is
transplanted.
that:

However, In interpreting the data one should consider

first, the method, may not be sensitive enough to detect decreased

IgE responsiveness.

For example, in experiment I four fold differences

were noted between the IgE levels of tumor-bearing mice and the controls.
These are suggestive differences, but as two fold differences occurred
among groups of animals treated identically just prior to the tumor
transfer, this four fold difference might be within experimental limits.
IgGl levels supposedly reflect levels of total antibody response.

230

Our data also suggest that tumor-bearing mice made a decreased IgGl
response, but again the limited sensitivity of the method makes such a

Effect of B16 on secondary response to antigen
Table X Experiment V

# of
Animals

Tumor Day Antigen
Dose Given Relative
Strain
to tumor
# of
cells
transfer

IgE titer
6

♦Day
13

IgGj titer
20

6

♦Day
13

20

4

C57

10?S.C.

-34,-6

160

40

10

40

> 320

< 160

4

C57

None

-34,-6

80

40

20

160

> 320

160

♦Number of day is relative to last exposure to antigen
Titers from Day 6 were obtained from serum just prior
to tumor transplant
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conclusion difficult.

Evidence in man supports the idea of a de¬

creased antibody response in individuals with malignancybut
reports of normal antibody responses have also been published,

209
7

Second, with PCA, iCA, one measures IgE titers for a specific antigen
while reports in the literature have been concerned with total serum
IgE,

Several studies have shown generally normal or elevated levels

of other immunoglobulins in most paitients with cancer,25/»2o0
this may not be indicative of responsiveness to a specific antigen.
Finally, to draw conclusions about human responses on the basis of
animal work can be difficult.

The most recently published study sug-

gests that IgE levels are normal in patients with cancer.

231

Our data

are not inconsistent with this concept.
The kinetics of the normal IgE response should be compared to
the IgGl response.

IgE levels declined steadily after the booster dose

of antigen, while the level of IgGl tended to maintain itself or even
rise slightly.

The data suggest a more marked decline in IgE than IgGl,

This might be explained in part by the muck shorter half life of IgE,^"^
at least in human studies, so that decreased immunoglobulin production
following antigen exposure would become evident sooner for IgE than IgGl.
As mentioned in the literature review, Hodgkin's disease is unique
among malignancies in that IgE levels are clearly elevated.

Debate

exists as to whether Hodgkin's disease is a T-cell or B-cell malignancy.
The traditional view was that Hodgkin's disease must be a T-cell malig39
nancy because T-cell function both as judged in vivo77 and in vitro is
depressed.

3

'

6> 8

Recent evidence, however, suggests that T-cells in

53
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Hodgkin's disease may be quite normal, only depleted in peripheral
blood.

152

Some claim that the relative number of E-cells is also

often diminished

68

and others suggest that the characteristic Reed-

Sternberg cell has Surface immunoglobulin and thus is of B-cell
origin.

12 h,

Perhaps the concept of T or E-cell malignancy is simply

not relevant to this disease.
Regardless of which cell is primarily involved, unquestionably
a depressed level of T-cell response often characterizes the disease.
A wealth of excellent experimental data is now accumulating to eluc¬
idate the role of T-cells in controlling IgE responses*^*224,225 anj
the depressed T-cell function is one explanation of the elevated IgE.^°
?31

Unfortunately, as alluded to previously, studying IgS responses

in the mouse model of Hodgkin's disease, the SJL, is most difficult
because at present they are thought to make poor IgE responses.

The

use of the lymphoma, L51?8Y, seemed to offer a possible i^ay to abrogate
tile T-cell control of IgE responses in mice.
positive;

169

This lymphoma is theta

that is, it bears an antigen marker attributed to lympho¬

cytes of thymic origin.

Speculation prior to the experiment was that a

T-cell malignancy might be characterized by heightened IgE production.
Most manipulations that destroy T-cell function including radiation,

J

anti-thymocyte serum,and thymectomy,"^ generally predispose to in¬
creased IgE production.
in our experiments.

Increased IgE production clearly was not found

Several explanations for this seem reasonable.

First, although T-cells may be affected by L5178Y, their function,

or at least their suppressor cell function, may be preserved.
Second, as T-cells are known to exert both a helper
pressor

225

and a sup-

223
J effect over IgE production, perhaps affecting both

equally allowed relatively normal IgE production.

Third, the malig¬

nancy may have affected only a subset of all T-cells, leaving intact
the subset vital for IgE response.

Fourth, a tumor maintained in

vivo or in vitro over a period of years may change its antigenic
properties.

Although we used the 'same9 tumor that other investiga¬

tors have found to be theta positive, only our own testing could verify
this for our cell line,

Finalljr, a transplanted malignancy might

proliferate but leave the animal’s indigenous lymphocytes functioning
relatively normally.
Acute lymphocytic leukemia may be derived from T-cells.

112

In

the few patients in whom it has been studied, IgE levels seem normal in
this disease.

The tumor most clearly bearing T-cell determinants in

man is the Sezary cell.

We are unaware of IgE levels having been mea¬

sured in tills disorder.
Finally, the decreased. IgE levels in the mice given frozen tumor
suggests a very speculative explanation.
being one example under study,

Viral infections, with measles

62 l6 3
1

D are known to affect immune respon¬

siveness and remission of allergic symptoms has been described following
measles vaccine.

^

Perhaps the diminished IgE response and subsequent

death of these animals was due to an activation of a latent virus from
the frozen, lysed cells.
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(C) Serum levels of IgE in childhood neoplasia

If IgE confers a genetic selective advantage, this survival
benefit must be present prior to child-bearing ago.

We wished,

therefore, to measure IgE levels in children with neoplasias.

As

children normally have low levels of IgE which rise gradually into
adolescence, we needed a radioimmunoassay that was particularly sen¬
sitive to low serum values.

As explained in Part II, such an assay

was not commercially available at the time of this stu^y and so serum
from children with a variety of tumors was collected and stored at
-20°C for future investigation.
Some limitations on the measurement of total serum IgE in cases
of neoplasia deserve comment.

First, neoplasms represent a variety of

entities, each with a theoretical variety of causes.

Even limiting

study to childhood neoplasia, we had collected samples which included
acute lymphocytic leukemia, acute undifferentiated leukemia, lympho¬
sarcoma, neuroblastoma, osteogenic sarcoma, and thyroid carcinoma.

If

total serum IgE is significant for any specific entity, this might be
overlooked by considering all neoplasms together.

Second, total serum

IgE may be irrelevant as it might not reflect tumor-specific IgE.

Normal

levels of IgE vary widely so that a great deal of tumor-specific anti¬
body might be present but not be reflected in total serum levels.

Fin¬

ally, finding abnormal levels of IgE would still leave the cause a mys¬
tery,
result?

Did low (or high) IgE predispose to malignancy or arise as a

(D) Tumor-Specific IgE Responses in Kan

Almost a decade before the discovery of IgE as a unique class of
immunoglobulins, a report was published indicating that IgE could be
involved in the antt-tumor immune response of some individuals.

The

work of GraceCurtis^ and co-workers showing that patients with
cutaneous manifestations of malignancy had immediate wheal and flare
reactions to their tumors established that IgE was involved, even
though IgE was not known to be a separate antibody class at the time.
Our studies designed to demonstrate that some individual do make
an IgE response against tumors had two purposes.
wished to verify the previous reports.

First, we merely

Second, if we could readily

develop a method to determine if a given individual was making an IgE
response, then the implications of this response could be system¬
atically evaluated.

For example, what is the effect of IgE on the

course and prognosis of the tumor?

What characterizes the tumors and

the individuals who tend to produce the IgE response?

Does the presence

of an IgE response suggest therapy?
The same method available to Grace and Curtis, namely the P-K re¬
action, was not available to us.

Current ethical standards would not

permit the transfer of solubilized human tumors to volunteers.

There¬

fore, two alternative methods to establish the presence of an IgE response
were evaluated, immunofluorescence and histamine release.
with the former are described;
investigated.

The results

the latter method is currently being
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Most of the studies involve breast carcinoma because 1) five

74

of Grace's patients had this disease,'

2) Black's data on skin

windows shows that basophils are prognostically significant in breast
cancer,and 3) the disease is common enough so that tissue was
readily available.

We were unable to obtain tissue on any patient

who had a cutaneous sign of malignancy.
Methods;
Tissue-

All tissue was obtained either from surgical pathology or

directly from the operating room usually within sixty minutes of its
removal and often in less time.

Tissue from 21 patients was obtained.

Malignant tiss^^e came from nine females with breast carcinoma and one
with a breast sarcoma.

Control tissue included sections from two re¬

duction raammoplasties, biopsies from five cases of fibrocystic dis¬
ease, breast tissue from a majre with gynecomastia, and a spleen free
of tumor from a patient with Hodgkin’s disease.

Tonsils and nasal

polyps were obtained to provide positive controls.

Immediately after

its receipt, all tissues were frozen in liquid nitrogen and then
stored at -90°C,

Within a few weeks of its surgical removal, tissues

were allowed to come to a temperature of -20°C and sectioned at a
thickness of four to six microns with a cryostat.

These sections were

placed on microscope slides and stored at -90° C in sealed containers until
ready for use, usually within a week or two.

On one occasion, tissue

from a patient with fibrocysiic disease was obtained directly from sur¬
gical pathology and immunofluorescence was performed without the inter¬
vening storage of tissue.

58

-

Antisera-

-

Commercial antisera to human immunoglobulin G and E

prepared in goats were purchased from Meloy Laboratories, Springfield, Va.

These antisera were fluoresceinated with a fluorescein

to protein ratio of 3.3 ug/mg for the anti-IgE and 6.2 ug/mg for
the anti-IgG,

Fluoresceinated antisera to human IgA and to rat

immunoglobulin produced in goats were given to us by Dr. Michael
ICashgarian.

These had been purchased from Hyland Laboratories.

All

antisera were diluted with saline at a ratio of 1:5 except for the
anti-IgG which was diluted 1:10.
Sera-

Serum from the respective patients was obtained from the blood

bank.

Serum was diluted 1:10 with saline before use.

Immunofluorescence-

Both direct and indirect immunofluorescence studies

were usually performed.

For indirect immunofluorescence one step in the

procedure must involve incubation of the tissue with serum prior to the
incubation with antiserum.
omitted.

For direct immunofluorescence this step is

The direct technique detects antibody on the surface of the

cell, while the indirect procedure looks for antibody in the serum that
has become attached to cellular antigen
Slides were taken from the freezer at -90° C and allowed to come
to room temperature before removing them from their sealed containers.
Slides were then washed with agitation in phosphate buffered saline (PBS)
for ten minutes.

Slides were dried and placed over a moistened piece

of filter paper.

The tissue was then covered with the appropriate serum

or antiserum.

After a thirty minute incubation at 37° C slides were

washed twice for ten minute periods in PBS while being shaken on a
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For direct immunofluorescence, slides were next dried,

the tissue covered with a drop of phosphate buffered glycerine, and
a coverslip put in place.

For indirect studies, slides were subjected

to a second incubation at 37°C, this time with appropriate antisera,
and then two more ten minute washes were performed prior to being
covered.

Slides were viewed within hours of completion of the staining

with a Zeiss microscope equipped with ultraviolet light.
Histology-

Hematoxylin and eosin (E&E) sections and phase contrast

microscopy were performed with some of the sections in order to localize
the areas of fluorescence.
Results:
Initial studies involved only the Keloy antisera to IgG and IgE.

These

studies indicated, that the sections from four of six patients with
malignancy stained with both of the fluoresceinated antisera after
direct and indirect immunofluorescence.

Tissue from the five patients

with fibrocystic disease and the two patients with reduction mammoplas¬
ties stained with anti-IgG consistently, but never significantly with
anti-IgE.

Both benign and malignant tissue stained occasionally with

anti-IgE in areas of vascular smooth muscle.

Such staining was not

considered positive.
With the help of Dr. Michael Ka'shgarian, H & E stains of the slides
were prepared.

Examining the slides under light and phase contrast

microscopy verified that the immunofluorescence in the positive specimens
was predominantly over the area of malignant cells.
control of fluoresceinated anti-rat

However, when the

immunoglobulin was added to the

procedure, this antiserum too stained the areas with malignant
tissue in a pattern identical to that obtained with anti-IgE.
Some of the tissues collected including the sarcomatous breast
and the spleen from the paitent with Hodgkin's disease have not
been sectioned but remain in storage in -90°C.

Their ultimate use

will depend upon the progress of further immunofluorescence studies.
Discussion;
Immunofluorescence as a technique for demonstrating a humoral
immune reaction to a tumor was first described by Klein et a|.
patients with Burkitt's lymphoma.
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"While immunofluorescence has been

used to locate IgE in such diverse studies as those on nasal polyps,

18

03 q
70
the thyroid in Graves' disease, J' the kidney in the nephrotic syndrome,

!33 and peripheral blood lymphocytes in a variety of disease states,^*6?,

± we are yn^are of any previous study that has used immuno¬
fluorescence to investigate the role of IgE in response to a solid tumor.
Our initial results were extremely encouraging, but performance
of adequate controls indicated that this enthusiasm was premature.

The

artifactual staining of tumor tissue may be due to a number of factors
including necrosis of the cells despite our diligence in freezing the
tissue as rapidly as possible.

The malignant cells may be more sensi¬

tive to the experimental conditions and thus they attracted the anti-IgE
while the benign tissue samples may have had less necrosis.
does have significant local immunoglobulin production

Breast tissue

^ and this

might explain the staining for anti-IgG in all tissues, benign and
malignant.

Another possibility is that these malignant cells are especi-

-61ally cytophilic for proteins.
Immunofluorescence studies not involving IgE have been performed

188

with breast carcinoma."0

However, these studies involved tumor cells

that have been grown in culture.

With such a system, one can more

easily control the staining procedure and artifact by using a set
number of cells for each trial.
carcinoma

25?

As human tumors including breast

tend to have common antigenic determinants, a single tumor

groid.ng in culture could be used to test sera of numerous patients
with the technique of indirect immunofluorescence.

Such testing would

assume that the common antigen(s) is the one recognised by IgE.

While

breast carcinoma is not considered one of the easier tumors to grow in
culture, cells obtained from pleural effusions secondary to the tumor
do grp® fairly readily in vitro.
We are currently approaching the problem of demonstrating that
some individuals produce tumor-specific IgE with the use of a histamine
release assay.

Basophils in high concentration can be found among the

leukocytes from blood sedimented with dextran or Ficoll-Hypaque,

26/i
v

If

a paitent has produced IgE specific for his tumor, this IgE should have
passively sensitized his own basophils.

Adding solubilized tumor antigen

to these leukocytes should cause the release of histamine as the cell
degranulates.
If human tumors do cause the release of histamine, the implications
may relate to both pathogenesis and therapeutics.

Histamine or other

vasoactive substances released by IgE may be implicated in the cutaneous
signs of some tumors.

And substances that block or neutralize the pro-

-62ddcts of an

IgE-antigen reaction would be logical pharmacologic

agents to evaluate.
Paradoxes in evaluating the putative IgE response to tumors
are plentiful.

The data on CBH suggests that the basophil can play

a role in tumor rejection, while the present understanding of his¬
tamine’s effect on the immune response suggests that it should ham¬
per tumor rejection.

Work with adjuvants like E. pertussis implies

to some that a tumor-specific IgE response is beneficial, but re¬
ports on cutaneous manifestations of malignancy suggest that IgE
may be -the culprit.

IgE is elevated in Hodgkin's disease presumably

secondary to depressed T-cell function, but lowered T-cell function
is found often in malignancy and IgE levels are either normal or low.
Is atopy related to the tendency to make a tumor-specific IgE response?
Do skin signs appear in the absence of an IgE response?
response occur in the absence of skin signs?
to dermatologic disease?

Does an IgE

Why should IgE be related

A histamine release assay is a reliable,

reproducible technique that should greatly facilitate the answering
of these questions.
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SIMURY

The possible role of IgE in response to neoplasia is reviewed with
speculations offered about the possible implications of this res¬
ponse.

Experimental efforts were divided bwtween basic research

on IgE and studies directly involving tumors.

Of the basic studies ,

A) the use of a solid phase radioimmunoassay (RIA) was perfected;
B) evaluation of diurnal rhythms awaits commercial availability or
a more sensitive, reproducible assay; and C) preliminary work on the
ontogenetics of IgE suggests that its synthesis may be independent
of the prior maturation of IgM bearing cells.

Of the tumor-related

studies, A) the demonstration in animals of IgE specific for tumor
antigen has progressed so that its accomplishment should be attain¬
able; B) the studies on IgE responses to ovalbumin in tumor-bearing
mice suggest that the tumor-bearing animals make antibody responses
nearly comparable to controls even with the transplantion of a theta
positive lymphoma; C) the work on IgE levels in childhood malignan¬
cies must await the aforementioned RIA; and D) studies now in pro¬
gress are attempting to demonstrate IgE responses to tumors in human
subjects with the use of immunofluorescence and a histamine release
assay.
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